The most arresting voice belongs to Martinha Brito, a 47-year-old from Viçosa do Ceará in north-eastern Brazil, who tells her 200,000 followers that she is slowly becoming “a living statue.” Diagnosed with Fibrodysplasia Ossificans Progressiva (FOP)—a genetic disorder in which injured soft tissue morphs into bone—Brito uses deadpan humour to narrate a reality in which bathing and sleeping become architectural challenges. Her videos, viewed millions of times, offer a corrective to a diagnostic journey that took decades; she was born with malformed big toes, a textbook early sign, yet went unidentified for years in a region where the disease’s prevalence, roughly one in two million, makes it all but invisible to primary care.

Thousands of kilometres north, similar patterns of dismissed symptoms have emerged among American women whose conditions are only slightly less rare. In Chicago, Melony Aponte was 20 when she first noticed muffled hearing and a persistent ring in her left ear. She attributed it to stress and loud music, and clinicians suspected a buildup of wax. Five years later, an MRI revealed an acoustic neuroma, a benign brain tumour with an annual incidence of about one in 100,000. Like Brito, Aponte now recounts those overlooked warnings on social media, part of a growing cohort of patients who believe their own testimony can compress the time to diagnosis for strangers. Further west, in Saint Joseph, Missouri, Sara Kasperowicz was born with Neurofibromatosis Type 1, a genetic condition affecting roughly one in 3,000 Americans, and had long accepted the 28 tumours scattered across her body. When a growth on her left wrist began expanding during pregnancy in 2022, doctors repeatedly dismissed it as a cyst. Only after persistent advocacy was it identified as a nerve tumour requiring intervention.

Viewed from São Paulo, Brito’s viral reach functions as a grassroots public-health campaign, demystifying a condition that most Brazilian physicians will never see. Analysts in London note that the digital sphere is replicating, in fast-forward, the support-group model that historically took decades to build for orphan diseases. While FOP turns muscles into a second skeleton, and NF1 litters the nervous system with benign masses, the psychological trajectory is strikingly similar: years of medical gaslighting, a chance encounter with a specialist, and then a decision to broadcast the private ordeal to a public that often replies with both curiosity and derision.

Scientists are beginning to treat these online archives as de facto natural-history registries, mining them for clues about disease progression that traditional clinical trials, hampered by tiny patient populations, cannot easily capture. The risk, as researchers in Washington caution, is that the same platforms that offer solidarity also amplify misinformation. Yet for Brito, Aponte and Kasperowicz, the ledger tilts overwhelmingly toward agency. In a global medical landscape still oriented toward common ailments, their feeds are not merely personal diaries but acts of cartography, mapping the contours of bodies that mainstream medicine has long left uncharted.